CoChat
Sign Up
Cited by 34Mangiferin and Mango ExtractsInflammasome and immune disordersInflammation biomarkers and pathways

Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation

Open access
Li, Ning, Xiong, Rui, He, Ruyuan, Liu, Bohao, Wang, Bo, Geng, Qing·2021·Journal of Inflammation Research
DOI 10.2147/jir.s304492PMC PMC8178744
Open this paper in CoChat — free accountOpen PDF

Abstract

SCOPE: Mangiferin (MF) is a natural phytopolyphenol, which displays potential pharmacological properties involving antibacterial, anti-inflammation, antioxidant and anti-tumor. However, little is known about the roles of MF in lung injury. The aim of this study is to demonstrate the modulatory effects and molecular mechanisms by which MF operates in sepsis-induced lung injury. METHODS AND RESULTS: To examine the protective properties of MF, an in vivo model of lipopolysaccharide (LPS)-induced lung injury in mice and an in vitro model of LPS-treated J774A.1 cells were established, respectively. The results revealed that MF treatment significantly relieved LPS-induced pathological injury and inflammatory response in murine lung tissues. Meanwhile, MF treatment also inhibited nucleotide-binding oligomerization domain (NOD)-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome activation and pyroptosis induced by LPS. In macrophage-specific NLRP3 deficiency mice treated with LPS, MF showed little protective effects. NLRP3 overexpression by adenovirus could also offset the beneficial effects of MF in LPS-treated J774A.1 cells. Furthermore, we found that MF could suppress the expression of NLPR3 and pyroptosis of macrophages by inhibiting the nuclear translocation of the nuclear factor-κB (NF-κB) subunits P50 and P65. CONCLUSION: MF protects against lung injury and inflammatory response by inhibiting NLRP3 inflammasome activation in a NF-κB-dependent manner in macrophages, which provides a promising therapeutic candidate for the treatment of lung injury.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/jir.s304492

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In acute lung injury models, MGF reduces inflammatory cytokine production and ameliorates pulmonary pathology.

    “This results in reduced inflammatory cytokine production and amelioration of pulmonary pathology (126).”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [126]

  • In models of acute lung injury, pre-administration of MGF (100 mg/kg) suppresses LPS-induced NLRP3 inflammasome activation in macrophages via NF-κB inhibition.

    “In models of acute lung injury, pre-administration of MGF (100 mg/kg) suppresses LPS-induced NLRP3 inflammasome activation in macrophages via NF-κB inhibition.”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [126]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 25

  1. [1]Matthay M, Arabi Y, Siegel E, et al. Phenotypes and personalized medicine in the acute respiratory distress syndrome. Intensive Care Med. 2020; 46(12): 2136– 2152. doi: 10.1007/s00134-020-06296-9 33206201 PMC7673253 · DOI
  2. [3]Zhang D, Song D, Shi L, et al. Mechanisms of interactions between lung-origin telocytes and mesenchymal stem cells to treat experimental acute lung injury. Clin Transl Med. 2020; 10(8): e231. doi: 10.1002/ctm2.231 33377639 PMC7724099 · DOI
  3. [4]Feng Y, Tan Z, Wu L, Dong F, Zhang F. The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res Rev. 2020; 64: 101192. doi: 10.1016/j.arr.2020.101192 33059089 · DOI
  4. [5]Chauhan D, Vande Walle L, Lamkanfi M. Therapeutic modulation of inflammasome pathways. Immunol Rev. 2020; 297(1): 123– 138. doi: 10.1111/imr.12908 32770571 PMC7497261 · DOI
  5. [6]Ning L, Wei W, Wenyang J, Rui X, Qing G. Cytosolic DNA-STING-NLRP3 axis is involved in murine acute lung injury induced by lipopolysaccharide. Clin Transl Med. 2020; 10(7): e228. doi: 10.1002/ctm2.228 33252860 PMC7668192 · DOI
  6. [7]Ying Y, Mao Y, Yao M. NLRP3 inflammasome activation by MicroRNA-495 promoter methylation may contribute to the progression of acute lung injury. Mol Ther Nucleic Acids. 2019; 18: 801– 814. doi: 10.1016/j.omtn.2019.08.028 31734560 PMC6861628 · DOI
  7. [9]Zhang L, Huang C, Fan S. Mangiferin and organ fibrosis: a mini review. Biofactors. 2020. 33217771
  8. [10]Naraki K, Rezaee R, Mashayekhi-Sardoo H, Hayes A, Karimi G. Mangiferin offers protection against deleterious effects of pharmaceuticals, heavy metals, and environmental chemicals. Phytother Res. 2020; 35(2): 810– 822. doi: 10.1002/ptr.6864 32961631 · DOI
  9. [11]Fan K, Ma J, Xiao W, et al. Mangiferin attenuates blast-induced traumatic brain injury via inhibiting NLRP3 inflammasome. Chem Biol Interact. 2017; 271: 15– 23. doi: 10.1016/j.cbi.2017.04.021 28455230 · DOI
  10. [13]Dong M, Li L, Li G, et al. viaMangiferin protects against alcoholic liver injury suppression of inflammation-induced adipose hyperlipolysis. Food Funct. 2020; 11(10): 8837– 8851. doi: 10.1039/D0FO01436B 32969440 · DOI · Paper page
  11. [14]Duan J, Zhou Y, Zhou A, et al. Calcitonin gene-related peptide exerts anti-inflammatory property through regulating murine macrophages polarization in vitro. Mol Immunol. 2017; 91: 105– 113. doi: 10.1016/j.molimm.2017.08.020 28892747 · DOI
  12. [15]Surabhi S, Cuypers F, Hammerschmidt S, Siemens N. The role of NLRP3 inflammasome in pneumococcal infections. Front Immunol. 2020; 11: 614801. doi: 10.3389/fimmu.2020.614801 33424869 PMC7793845 · DOI
  13. [16]Zhang Y, Li X, Grailer J, et al. Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J Pineal Res. 2016; 60(4): 405– 414. doi: 10.1111/jpi.12322 26888116 · DOI
  14. [17]Mahalanobish S, Saha S, Dutta S, Sil P. Mangiferin alleviates arsenic induced oxidative lung injury via upregulation of the Nrf2-HO1 axis. Food Chem Toxicol. 2019; 126: 41– 55. doi: 10.1016/j.fct.2019.02.022 30769048 · DOI
  15. [18]Zou B, Wang H, Liu Y, et al. Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3. Oncol Rep. 2017; 38(3): 1431– 1441. doi: 10.3892/or.2017.5814 28714011 PMC5549032 · DOI · Paper page
  16. [19]Jia L, Sun P, Gao H, et al. Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-β1/Smad2/3 pathway. J Pharm Pharmacol. 2019; 71(6): 1017– 1028. doi: 10.1111/jphp.13077 30847938 · DOI
  17. [20]Wu J, Sun J, Meng X. Pyroptosis by caspase-11 inflammasome-gadermin D pathway in autoimmune diseases. Pharmacol Res. 2021; 165: 105408. doi: 10.1016/j.phrs.2020.105408 33412278 · DOI
  18. [21]Zhang Z, Zhang Y, Lieberman J. Lighting a fire: can we harness pyroptosis to ignite antitumor immunity? Cancer Immunol Res. 2021; 9(1): 2– 7. doi: 10.1158/2326-6066.CIR-20-0525 33397791 PMC7789047 · DOI
  19. [22]Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J. 2021; 40(5): e106700. doi: 10.15252/embj.2020106700 33439509 PMC7917554 · DOI
  20. [23]Camilli G, Blagojevic M, Naglik J, Richardson J. Programmed cell death: central player in fungal infections. Trends Cell Biol. 2020; 31(3): 179– 196. doi: 10.1016/j.tcb.2020.11.005 33293167 PMC7880884 · DOI
  21. [24]Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020; 13(1): 110. doi: 10.1186/s13045-020-00946-7 32778143 PMC7418434 · DOI
  22. [25]Abu Khweek A, Amer A. Pyroptotic and non-pyroptotic effector functions of caspase-11. Immunol Rev. 2020; 297(1): 39– 52. doi: 10.1111/imr.12910 32737894 PMC7496135 · DOI
  23. [26]Kovarova M, Hesker P, Jania L, et al. NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice. J Immunol. 2012; 189(4): 2006– 2016. doi: 10.4049/jimmunol.1201065 22753929 PMC3635067 · DOI
  24. [27]He Y, Xu K, Wang Y, et al. AMPK as a potential pharmacological target for alleviating LPS-induced acute lung injury partly via NLRC4 inflammasome pathway inhibition. Exp Gerontol. 2019; 125: 110661. doi: 10.1016/j.exger.2019.110661 31319131 · DOI
  25. [28]Zhang H, Luo J, Alcorn J, et al. AIM2 inflammasome is critical for influenza-induced lung injury and mortality. J Immunol. 2017; 198(11): 4383– 4393. doi: 10.4049/jimmunol.1600714 28424239 PMC5439025 · DOI

Cited by

Sorted by citations

Authors
Li, N., Xiong, R., He, R., Liu, B., Wang, B., & Geng, Q.
Affiliations
Renmin Hospital of Wuhan University (CN)
Corresponding author
Wang, Bo
ORCID
Venue
Journal of Inflammation Research
Publisher
Informa UK Limited
Published
2021-05
Volume
Volume 14
Pages
2289-2300
ISSN
1178-7031 (ISSN-L)
DOI
10.2147/jir.s304492
PMC
PMC8178744
OpenAlex
W3169655583
Cited by
34
References
3
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2023: 11 · 2022: 9 · 2021: 2
FWCI
7.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Inflammation Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • National Natural Science Foundation of China (81800343, 81770095)
  • Fundamental Research Funds for the Central Universities (2042021kf0081)
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
mangiferin, sepsis-induced lung injury, NLRP3 inflammasome, pyroptosis, lipopolysaccharide, NF-κB nuclear translocation, macrophages, anti-inflammatory activity, lung inflammation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review